In low-risk patients, particularly those with hormonal subtypes or in the early stage with nodal negativity, the Ki-67 level emerges as a crucial factor to be considered in determining appropriate treatment for breast cancer patients. The gene discussed is MKI67; the disease is breast carcinoma.